At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
filgrastim +11 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY
In Brief
A Phase 2 clinical trial evaluating filgrastim, amifostine trihydrate, and 10 other interventions for Neutropenia and Sarcoma. Completed, enrolled 130 participants across 49 sites in 5 countries.
Detailed Summary
Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeutropenia, Sarcoma
CountriesAustralia, Canada, Puerto Rico, Switzerland, United States
CollaboratorsChildren's Cancer Group
Timeline
Phase 2CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 1995
Primary CompletionJun 2003
First PostedJun 2003
TodayJul 2026
First PostedJun 18, 2003
Enrollment StartApr 1, 1995
Primary CompletionJun 1, 2003
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 23.0 years ago
Interventions
filgrastimbiological
amifostine trihydratedrug
cyclophosphamidedrug
doxorubicin hydrochloridedrug
etoposidedrug
ifosfamidedrug
topotecan hydrochloridedrug
vincristine sulfatedrug
conventional surgeryprocedure
low-LET cobalt-60 gamma ray therapyradiation
low-LET electron therapyradiation
low-LET photon therapyradiation